Compliance And Treatment Satisfaction With Biological Treatments For Systemic Juvenile Idiopathic Arthritis (SJIA)

• Published in: Value in health 2017-10, Vol.20 (9), p.A558-A559
• Main Authors: Shenoi, S, Horneff, G, Cidon, M, Ramanan, A, Kimura, Y, Quartier, P, Foeldvari, I, Zeft, A, Lomax, K, Gregson, J, Mckenna, SJ, Abma, T, Campbell, S, Weiss, J, Marinsek, N, Patel, D, Wulffraat, N
• Format: Article
• Language: English
• Subjects: Adherence; Arthritis; Caregivers; Children; Compliance; Efficacy; Idiopathic; Interleukin 1 receptor antagonist; Medical treatment; Memory; Patient compliance; Patient satisfaction; Questionnaires
• ISSN: 1098-3015; 1524-4733
• DOI: 10.1016/j.jval.2017.08.908

OBJECTIVES: To examine caregivers' treatment satisfaction and adherence with biologic treatments for SJIA METHODS: Within an international, non-interventional study to assess the burden of SJIA, a tailored questionnaire was developed to capture caregiver's' satisfaction with their child's current and past biological treatment experience for SJIA. Caregiver's satisfaction at the time of completing the questionnaire was assessed based on their perception of the efficacy, safety and convenience of each treatment and their child's adherence to it. RESULTS: Anakinra (N=41[32%])( canakinumab (N=29[48%]) and tocilizumab (N=31[48%]) were the three biologies captured. Respondents answered based on all treatment experience, regardless of current treatment. Caregivers perceived treatment satisfaction with canakinumab was consistently high and equal to or higher than caregivers' satisfaction with anakinra or tocilizumab. Significantly more caregivers were not stressed or anxious when their child received canakinumab (48%) and thought that canakinumab was convenient (69%), caused no burden to them (38%) and demonstrated complete improvement in symptoms (48%). In contrast, anakinra and tocilizumab were reported to be inconvenient by 58% and 48%, caused moderate to extreme burden in 64% and 71%, respectively, and anakinra had a high 'no improvement of symptoms' rate (24%). Overall, 41% of caregivers thought their child was not stressed or anxious receiving canakinumab compared to anakinra (12%) and tocilizumab (35%). Complete treatment compliance as follows: canakinumab (96%), anakinra (85%) and tocilizumab (81%). The main reasons for missing treatment were due to 'forgetting to give' or 'forgetting to take the treatment' in the anakinra group (17%) or the treatment was found to be 'inconvenient for practical reasons' in the tocilizumab group (9.8%). CONCLUSIONS: According to caregivers, biologic treatment completely improved SJIA symptoms in 48% of children on canakinumab or tocilizumab and 32% on anakinra. Canakinumab treatment was associated with higher treatment satisfaction and adherence compared to tocilizumab and anakinra for SJIA.